Our work suggests that stratifying patients with respect to SYK/FYN expression may open avenues to personalized medicine in SCLC, given that SYK small-molecule inhibitors are already in clinical trials for other disease conditions. This evidence concerns the gene SYK and small cell lung carcinoma.